SBIR/STTR Research Award
Novel treatment for Huntington???s Disease
Award amount
$224,512Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PROGENRA INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Z3JKMHXHFHJ6
- Solicitation number
- PA13-234
- Topic code
- NINDS
Research abstract
DESCRIPTION (provided by applicant): Because of their degeneracy and selective involvement in most cellular pathways, ubiquitin conjugating and deconjugating enzymes are being explored as therapeutic targets for treating many major diseases, including neurodegenerative disease. The proteasome-associated deubiquitylase (DUB) USP14 plays a key role in regulating proteasomal degradation of pathogenic proteins such as tau, TDP-43 and ?-synuclein. Huntington's disease (HD) is a progressive, fatal neurodegenerative disease initially characterized by chorea and gait disturbances. The causative factor is accumulation of polyglutamine (poly Q) expanded huntingtin (Htt) protein, which is polyubiquitylated, but accumulates in inclusion bodies (IBs), rather than being degraded by the proteasome. Results from in vivo models link enhanced degradation of poly Q expanded Htt with reversal of behavioral deficits. Since USP14 has been shown to inhibit degradation of pathogenic, neurotoxic proteins, it is hypothesized that
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Ubiquitin pathway modulators as novel antituberculosis drugs
- Ubiquitin pathway modulators for treating pancreatitis
- Parkin activators for cardioprotective therapies
- Development of ITCH-activating IRAK4 degraders as dual-targeting drug candidates for the treatment of rheumatoid arthritis
- Novel TXNIP degraders for treating diabetes
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families
- Commercialization Readiness Pilot for Flow Acceleration for Stroke Thrombolysis (FAST) System
- 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development
- Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries
- Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2: Supplement for Imaging System
Research funding history
53 SBIR/STTR records share this UEI (2003–2025). Reported award amounts total $22,552,905. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services